Litcius/Paper detail

Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial

Ilad Alavi Darazam, Shervin Shokouhi, Masoud Mardani, Mohamad Amin Pourhoseingholi, Mohammad Mahdi Rabiei, Firouze Hatami, Minoosh Shabani, Omid Moradi, Farid Javandoust Gharehbagh, Seyed Sina Naghibi Irvani, Mahdi Amirdosara, Mohammadreza Hajiesmaeili, Omidvar Rezaei, Ali Khoshkar, Legha Lotfollahi, Latif Gachkar, Hadiseh Shabanpour Dehbsneh, Negar Khalili, Azam Soleymaninia, Akram Hoseyni Kusha, Maryam Taleb Shoushtari, Parham Torabinavid

2021International Immunopharmacology38 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)Randomized controlled trialMedicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BetacoronavirusPandemicInternal medicineIntensive care medicineVirologyOutbreakInfectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchPharmacological Receptor Mechanisms and Effects
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial | Litcius